
Saurabh Zanwar/X
Dec 28, 2024, 17:33
Saurabh Zanwar: Is risk-adapted therapy ready for prime time in Multiple Myeloma?
Saurabh Zanwar, Assistant Professor at Mayo Clinic, shared on X about recent paper by him as first author titled “Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future” published on Taylor and Francis.
Authors: Saurabh Zanwar and Shaji Kumar
“Is risk-adapted therapy ready for prime time in Multiple Myeloma? Check out our recent review looking at risk definitions and MRD-guided therapy for MM.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 1, 2025, 17:02
Mar 1, 2025, 16:29
Mar 1, 2025, 15:32
Mar 1, 2025, 15:20
Mar 1, 2025, 15:12
Mar 1, 2025, 14:44
Mar 1, 2025, 14:24